Król A.1, Krawczyk A.1, Nowak M.3, Zarudzki L.2, Jurecka-Lubieniecka B.1, Hasse-Lazar K.1, Paliczka-Cieślik E.1, Krajewska J.1, Michalik B.1, Jarząb B.1 1Department of Nuclear Medicine and Endocrine Oncology, MSC Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland, 2Department of Radiodiagnostics, MSC Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland, 3Department Read More
Author: admin
OVEREXPRESSION OF SFRP2, ABCG1 AND CPXM1 IN BOTH GRAVES OPHTHALMOPATHY AND ARM LYMPHEDEMA
Vondrichova T.1,4, Parikh H.4, Brorsson H.2, Martensson T.2, Asman P.3, Groop L.1, 4, Hallengren B.1, 4, Lantz M.1, 4 1Department of Endocrinology, Malmö University Hospital, Malmö, Sweden, 2Department of Plastic Surgery, Malmö University Hospital, Malmö, Sweden, 3Department of Ophthalmology, Malmö University Hospital, Malmö, Sweden, 4Lund University, Department of Clinical Sciences Malmö, Diabetes and Endocrinology, Malmö, Read More
CORRELATION BETWEEN BRAFV600E MUTATION AND CLINICAL AND PATHOLOGICAL FEATURES OF PAPILLARY THYROID CARCINOMAS IN THE CZECH REPUBLIC
Sykorova V.1, Dvorakova S.1, Vaclavikova E.1, Ryska A.2, Kodetova D.3, Astl J.4, Duskova J.5, Smutny S.6, Vlcek P.7, Bendlova B.1 1Department of Molecular Endocrinology, Institute of Endocrinology, Prague, Czech Republic, 2Department of Pathology, Faculty of Medicine and University Hospital, Charles University, Hradec Kralove, Czech Republic, 3Institute of Pathology and Molecular Medicine, 2nd Medical Faculty, Charles Read More
BRAF EXPRESSION MAY HELP DEFINE PAPILLARY THYROID CANCER PROGNOSIS
Araujo P.PC1, Tincani A.J.2, Guilhen T.A.C.1, Morari C.E.1, Ward S. L.1 1Molecular Genetics of Cancer Laboratory, Department of Internal Medicine, Medical Science School – FCM, State University of Campinas – UNICAMP, State of Sao Paulo, Brazil, 2Head and Neck Division, Department of Surgery, State University of Campinas – UNICAMP, State of Sao Paulo, Brazil Abstract Read More
PRIMARY TUMOUR DIAMETER AS A RISK FACTOR FOR METASTASES IN DIFFERENTIATED THYROID CARCINOMA
Luster M., Verburg F., Mäder U., Reiners Ch. University Clinic W?rzburg, W?rzburg, Germany Abstract Objectives: In differentiated thyroid carcinoma a larger tumour diameter is considered to indicate a poorer prognosis. This higher risk is most likely effectuated due to a higher rate of metastases and locally invasive growth in patients with larger carcinomas. The aim Read More
PAPILLARY THYROID CANCERS
Perrino M.1, Vannucchi G.1, Colombo C.1, Vicentini L.2, Chiti A.3, Beck Peccoz P.1, Fugazzola L.1 1Department of Medical Sciences, Endocrine Unit Unviversity of Milan, IRCCS Fondazione Policlinico, Milan, Italy, 2Endocrine Surgery Unit, IRCCS Fondazione Policlinico, Milan, Italy, 3Nuclear Medicine Unit, IRCCS Istituto Clinico Humanitas, Milan, Italy Abstract The incidence of papillary thyroid cancer (PTC) is Read More
THE EFFECT OF PROLONGED ROSIGLITAZONE THERAPY IN PATIENTS WITH METASTATIC RADIOIODINE-NEGATIVE DIFFERENTIATED THYROID CARCINOMA
K?hne-Eversmann L.1, Weiss M.2, Pfluger T.2, Gaertner R.1 1Department of Endocrinology, Medizinische Klinik Innenstadt, University of Munich, 2Department of Nuclear Medicine, Innenstadt, University of Munich Abstract Objective: Patients with metastases of differentiated thyroid carcinoma that fail to trap iodine or are unresectable have a poor prognosis. Recent studies with PPAR-γ agonists have shown promising effects Read More
HSP90 INHIBITION AS A NOVEL THERAPEUTIC APPROACH FOR THE TREATMENT OF AGGRESSIVE THYROID CARCINOMAS
McMillin W.D.1, Kotoula V.2, Negri J.1, Hayden P.1, Koletsa T.2, Mitsiades S.C.1, Mitsiades N.1, 3 1Department of Medical Oncology, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston MA, USA, 2Department of Pathology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece, 3Memorial Sloan Kettering Cancer Center, New York, USA Abstract Context: Read More
PNEUMOTHORAX DUE TO MASSIVE TUMOR LYSIS IN A PATIENT WITH SORAFENIB THERAPY FOR METASTASIZED DIFFERENTIATED THYROID CARCINOMA
Hoftijzer H.1, Heemstra K.1, Blaauwwiekel E.2, Corssmit E.1, Romijn J.1, Smit J.1 1Department of Endocrinology and metabolism, Leiden University medical Center, Leiden, The Netherlands, 2Department of Internal Medicine, Nij Smellinghe Hospital, Drachten, The Netherlands Abstract Background: Treatment options for metastases of differentiated thyroid carcinoma with absent uptake of radioiodine (RaI) are limited. Broad spectrum tyrosine Read More
ANTI-TUMOR EFFECTS OF THE TYROSINE KINASE INHIBITORS SUNITINIB (SU11248) AND VANDETANIB (ZD6474) IN HUMAN THYROID CARCINOMA CELL LINES
Charalambous E.1,2, Kotoula V.1, Hayden P.2, McMillin W.D.2, Negri J.2, Mitsiades S.C.2, Mitsiades N.2, 3 1Department of Pathology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece, 2Department of Medical Oncology, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston MA, USA., 3Memorial Sloan Kettering Cancer Center, New York, USA Abstract Context: Read More